PARP inhibitors are a promising new class of ovarian cancer drugs, and the number of women known to benefit from them is on the rise. The goal of PARP inhibitors is to maintain the progress made by your surgery and chemotherapy. That’s why doctors refer to PARP inhibitors as something called “maintenance therapy.”
The good news is that almost all women are now eligible for PARP inhibitors sometime during their treatment. Having said that, the question as to when someone may be eligible to receive PARP inhibitors depends on several factors, including genetic characteristics.
For example, women with BRCA mutations tend to respond best to PARP inhibitors. These women may be able to take PARP inhibitors early on in their treatment, after their initial surgery and chemotherapy.
If, however, you don’t have a BRCA mutation, you may be a candidate to go on PARP inhibitor maintenance after your cancer returns if you responded to your chemotherapy. These factors make it crucial to consider genetic testing after your ovarian cancer diagnosis. Right now, only about 40 percent of women with ovarian cancer treatment get genetic testing done — making it important that you bring it up with your doctor.
Another factor that determines who can benefit from PARP inhibitors is chemotherapy response. In general, Dr. Lyndsay Willmott says, patients need to have at least some response to chemotherapy to be eligible to receive PARP inhibitors.
Most recently, the American Society of Clinical Oncology (ASCO) released new guidelines recommending PARP inhibitors be offered to women, with or without genetic mutations, who are newly diagnosed with stage III or IV ovarian cancer and have improved with chemotherapy.
“Again, maintenance essentially is when you finish your chemotherapy, and you go on to a different kind of medication to try to maintain the effect of that chemotherapy,” Dr. Willmott says.
How PARP Inhibitors Work
One of the key things to know about PARP inhibitors is that your genetic makeup and specific features of your cancer will have a significant impact on how effective these drugs may be. Experts tell SurvivorNet that every woman with ovarian cancer should get a genetic test to determine if they have a mutation called BRCA, because the mutation enables PARP inhibitors to function much more powerfully. Importantly, there is increasing data that even women without BRCA mutations can still derive some benefit from these drugs.
PARP inhibitors interrupt the process of single stranded DNA repair, an essential part of cell replication. Defects in DNA repair ultimately cause cell death. PARP inhibitors work best when there is a second error in DNA repair, such as that caused by a mutation in BRCA. BRCA is a critical player in homologous recombination, a highly effective double stranded DNA repair process. BRCA is not the only important part of homologous recombination, other genes are involved. The label homologous recombination deficient (HRD) indicates a tumor which has one of many possible errors in the double stranded DNA repair process of homologous recombination.
Newly-Diagnosed Epithelial Ovarian Cancer
The PARP inhibitor Zejula (niraparib) has been approved by the FDA for all women with newly-diagnosed ovarian cancer irrespective of whether the tumor is HRD. The drug is used after successful treatment with a platinum-based chemotherapy, the mainstay chemotherapy for ovarian cancer.
Due to limited benefit in progression free survival seen in the absence of HRD, gynecologic oncologists differ on whether PARP inhibitors should be universally recommended in the “upfront maintenance setting.” Each patient should be made aware of risks and benefits to PARP inhibitor maintenance and decide with their oncologist what is the best treatment plan for them.
The PARP inhibitor Lynparza (olaparib) is approved for women newly diagnosed with ovarian cancer and with a germline or somatic mutation in BRCA1/2.
Lynparza is also approved in combination with Avastin (bevacizumab) for women with HRD. Avastin is a blood vessel growth inhibitor, which works by starving the tumor of vital nutrients needed to grow.
Using PARPs to Treat Recurrence
Unfortunately, too often, ovarian cancer comes back.
For women with ovarian cancer who have had a recurrence and responded to platinum-based chemotherapy, Lynparza, Zejula and another PARP inhibitor called Rubraca (rucaparib) are FDA approved for use as a maintenance therapy, regardless of whether a woman has a BRCA mutation or HRD.
For some women who have had prior chemotherapy treatments, Rubraca, Zejula or Lynparza may also be options. These uses are based on factors such as number of prior therapies and BRCA mutation or HRD.
The different PARP inhibitors do have some varying side effects, which oncologists need to evaluate carefully. Some of these considerations are explained here.
Learn more about SurvivorNet's rigorous medical review process.
Dr. Lyndsay Willmott is a gynecologic oncologist at Arizona Oncology. Read More
PARP inhibitors are a promising new class of ovarian cancer drugs, and the number of women known to benefit from them is on the rise. The goal of PARP inhibitors is to maintain the progress made by your surgery and chemotherapy. That’s why doctors refer to PARP inhibitors as something called “maintenance therapy.”
The good news is that almost all women are now eligible for PARP inhibitors sometime during their treatment. Having said that, the question as to when someone may be eligible to receive PARP inhibitors depends on several factors, including genetic characteristics.
Read More For example, women with BRCA mutations tend to respond best to PARP inhibitors. These women may be able to take PARP inhibitors early on in their treatment, after their initial surgery and chemotherapy.
If, however, you don’t have a BRCA mutation, you may be a candidate to go on PARP inhibitor maintenance after your cancer returns if you responded to your chemotherapy. These factors make it crucial to consider genetic testing after your ovarian cancer diagnosis. Right now, only about 40 percent of women with ovarian cancer treatment get genetic testing done — making it important that you bring it up with your doctor.
Another factor that determines who can benefit from PARP inhibitors is chemotherapy response. In general, Dr. Lyndsay Willmott says, patients need to have at least some response to chemotherapy to be eligible to receive PARP inhibitors.
Most recently, the American Society of Clinical Oncology (ASCO) released new guidelines recommending PARP inhibitors be offered to women, with or without genetic mutations, who are newly diagnosed with stage III or IV ovarian cancer and have improved with chemotherapy.
“Again, maintenance essentially is when you finish your chemotherapy, and you go on to a different kind of medication to try to maintain the effect of that chemotherapy,” Dr. Willmott says.
How PARP Inhibitors Work
One of the key things to know about PARP inhibitors is that your genetic makeup and specific features of your cancer will have a significant impact on how effective these drugs may be. Experts tell SurvivorNet that every woman with ovarian cancer should get a genetic test to determine if they have a mutation called BRCA, because the mutation enables PARP inhibitors to function much more powerfully. Importantly, there is increasing data that even women without BRCA mutations can still derive some benefit from these drugs.
PARP inhibitors interrupt the process of single stranded DNA repair, an essential part of cell replication. Defects in DNA repair ultimately cause cell death. PARP inhibitors work best when there is a second error in DNA repair, such as that caused by a mutation in BRCA. BRCA is a critical player in homologous recombination, a highly effective double stranded DNA repair process. BRCA is not the only important part of homologous recombination, other genes are involved. The label homologous recombination deficient (HRD) indicates a tumor which has one of many possible errors in the double stranded DNA repair process of homologous recombination.
Newly-Diagnosed Epithelial Ovarian Cancer
The PARP inhibitor Zejula (niraparib) has been approved by the FDA for all women with newly-diagnosed ovarian cancer irrespective of whether the tumor is HRD. The drug is used after successful treatment with a platinum-based chemotherapy, the mainstay chemotherapy for ovarian cancer.
Due to limited benefit in progression free survival seen in the absence of HRD, gynecologic oncologists differ on whether PARP inhibitors should be universally recommended in the “upfront maintenance setting.” Each patient should be made aware of risks and benefits to PARP inhibitor maintenance and decide with their oncologist what is the best treatment plan for them.
The PARP inhibitor Lynparza (olaparib) is approved for women newly diagnosed with ovarian cancer and with a germline or somatic mutation in BRCA1/2.
Lynparza is also approved in combination with Avastin (bevacizumab) for women with HRD. Avastin is a blood vessel growth inhibitor, which works by starving the tumor of vital nutrients needed to grow.
Using PARPs to Treat Recurrence
Unfortunately, too often, ovarian cancer comes back.
For women with ovarian cancer who have had a recurrence and responded to platinum-based chemotherapy, Lynparza, Zejula and another PARP inhibitor called Rubraca (rucaparib) are FDA approved for use as a maintenance therapy, regardless of whether a woman has a BRCA mutation or HRD.
For some women who have had prior chemotherapy treatments, Rubraca, Zejula or Lynparza may also be options. These uses are based on factors such as number of prior therapies and BRCA mutation or HRD.
The different PARP inhibitors do have some varying side effects, which oncologists need to evaluate carefully. Some of these considerations are explained here.
Learn more about SurvivorNet's rigorous medical review process.
Dr. Lyndsay Willmott is a gynecologic oncologist at Arizona Oncology. Read More
